Erratum: Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow up study (Transplantation (2010) 90 (786-790) DOI: 10.1097/TP.0b013e3181f09c89);Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study

Transplantation

Volumn 90, Issue 7, 2010, Pages 786-790

  Xie, Shi Bin ^a   Zhu, Jian Yun ^a   Ying, Zhang ^a   Zeng, Li Jiao ^a   Chao, Ma ^a   Lu, Min Qiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

HBV; Hepatitis B; Orthotopic liver transplantation; Recurrence

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; TREATMENT DURATION; VIRUS MUTATION;

EID: 77957993529     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000002820     Document Type: Erratum

References (28)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733.
2. Liu GT, Si CW, Wang QH, et al. Comments on the prevention and research of chronic hepatitis in China. Natl Med J China 2002; 82: 74.
3. Liang XF, Chen YS, Wang XJ,etal.Astudyonthe sero-epidemiology of hepatitis B in Chinese population aged over 3-years old: The report from Chinese Center for Disease Control and Prevention. Chin J Epidemiol 2005; 26: 655.
4. Wang XJ, Zhang RZ, Hu YS, et al. Analysis on epidemic status of viral hepatitis in China: The report from Chinese Center for Disease Control and Prevention. Dis Surveillance 2004; 19: 290.
5. Cui FQ, Wang XJ, Liang XF. Epidemiological analysis on reported hepatitis B under 15 years in China: The report from Chinese Center for Disease Control and Prevention. Chin J Vaccines Immun 2006; 12: 206.
6. Pfitzmann R, Nüssler NC, Hippler-Benscheidt M. Long-term results after liver transplantation. Transpl Int 2008; 21: 234.
7. Beckebaum S, Sotiropoulos GC, Gerken G, et al. Hepatitis B and liver transplantation: 2008 update. Rev Med Virol 2009; 19: 7.
8. Yilmaz N, Shiffman ML, Todd Stravitz R, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: A retrospective analysis spanning 20 years. Liver Int 2008; 28: 72.
9. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14(suppl 1): 37.
10. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of Hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with Lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903.
11. Angus PW, McCaughan GW, Gane EJ, et al. Combination low dose Hepatitis B immune globulin and Lamivudine therapy provides effective prophylaxis against posttransplantation Hepatitis B. Liver Transpl 2000; 6: 429.
12. Rosenau J, Bahr M, Tillmann HL, et al. Lamivudine and low-dose Hepatitis B immune globulin for prophylaxis of Hepatitis B reinfection after liver transplantation: Possible role of mutation in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895.
13. Seehofer D, Rayes N, Steinmüller T, et al. Occurrence and clinical outcome of Lamivudine-resistant Hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976.
14. Neff GW, O'Brien CB, Nerry J, et al. Outcomes in liver transplant recipients with Hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372.
15. Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of Lamivudine resistant Hepatitis B virus: Rapid resolution during treatment with Adefovir. Gut 2001; 49: 860.
16. Perillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess Lamivudine monotherapy before and after transplantation for chronic Hepatitis B. Hepatology 2001; 33: 424.
17. Mutimer D, Dushieko G, Barrett C, et al. Lamivudine without HBIG for prevention of graft reinfection by Hepatitis B: Long-term follow-up. Transplantation 2000; 70: 809.
18. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the Hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
19. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with Hepatitis B virus-related liver disease. Hepatology 1991; 13: 619.
20. Hwang S, Lee SG, Ahn CS, et al. Prevention of hepatitis B recurrence after living donor liver transplantation: Primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 2008; 14: 770.
21. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transplant 2004; 10: S74.
22. Lee HW, Suh KS, Yi NJ. Preoperative Lamivudine therapy in HBV DNA positive recipients: Is it always necessary? Hepatogastroenterology 2007; 54: 1783.
23. Liaw Y-F. Results of Lamivudine in Asian trials. Proceedings of EASL International Consensus Conference on Hepatitis B 2002. J Hepatol 2003; 39: S111.
24. Zoulim F. A preliminary benefit-risk assessment of Lamivudine for the treatment of chronic Hepatitis B virus infection. Drug Safety 2002; 25: 497.
25. Schiff ER, Lai C-L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant Hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419.
26. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of Hepatitis B e antigen positive Hepatitis B. N Engl J Med 2003; 348: 808.
27. Wai C-T, Prabhakaran K, Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant Hepatitis B post liver transplant. Transplant Proc 2004; 36: 2313.
28. Limquiaco JL, WongJ, Wong VW,etal. Lamivudine monoprophylaxis and Adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. J Med Virol 2009; 81: 224.